Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DNM1L | O00429 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12291575 | 0.81 | CKS1B (0.49) | — | |
| SCHEMBL14859271 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL21192403 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15164461 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2558910 | 0.77 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2223887 | 0.77 | OPRK1 (0.43) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL26111059 | 0.75 | GLS (0.44) | SMN1; SMN2NPC1RAB9AHPGDHRH3 | |
| SCHEMBL2554157 | 0.74 | MAPT (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4703857 | 0.73 | DRD2 (0.49) | SMN1; SMN2NPC1RAB9AHPGDHRH3 | |
| SCHEMBL23387302 | 0.73 | LMNA (0.48) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011130515-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SMN1; SMN2, MTPN, MORF4L1 | SMN1; SMN2 1/4885NPC1 2811/4885RAB9A 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.